Simona King - Jul 28, 2023 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role: Chief Financial Officer
Signature: /s/ Edgar Cale, Attorney-in-Fact
Stock symbol: PASG
Transactions as of: Jul 28, 2023
Transactions value $: -$10,079
Form type: 4
Date filed: 8/1/2023, 04:36 PM
Previous filing: Apr 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PASG	Common Stock	Options Exercise	$0	+31.3K	+744.58%	$0.00	35.4K	Jul 28, 2023	Direct	F1
transaction	PASG	Common Stock	Sale	-$10.1K	-11.5K	-32.31%	$0.88	24K	Jul 28, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PASG	Restricted Stock Units	Options Exercise	$0	-31.3K	-100%	$0.00^*	0	Jul 28, 2023	Common Stock	31.3K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3	Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer.